OraMed Enters Global Licensing Deal for Lidocaine Product

Published 27/02/2025, 23:10
© REUTERS/Ammar Awad

OraMed Pharmaceuticals Inc. (NASDAQ:ORMP), a pharmaceutical company specializing in the development of oral drug delivery systems with a market capitalization of $85 million and strong financial health metrics according to InvestingPro, has entered into a global licensing agreement with Scilex Pharmaceuticals Inc., as per the 8-K filing with the U.S. Securities and Exchange Commission.

On February 22, 2025, Scilex Pharmaceuticals granted OraMed’s subsidiary, RoyaltyVest Ltd., an exclusive license to develop, manufacture, and commercialize lidocaine-based products outside the United States and certain other territories. The agreement encompasses ZTlido, a lidocaine topical system, and SP-103, which are products developed by Scilex. The deal comes as OraMed maintains a robust balance sheet with minimal debt and a remarkable current ratio of 27.08.

OraMed has committed to use commercially reasonable efforts to obtain regulatory approval for the licensed lidocaine product in at least one major market country within 18 months from the effective date of the agreement. Additionally, the company is obligated to invest a minimum of $200,000 annually towards these efforts until regulatory approval is secured in the licensed territories.

The financial terms of the deal include a 50/50 split of net revenue generated from the sales of the product, with quarterly payments to Scilex Pharmaceuticals. Furthermore, Scilex is required to facilitate introductions and negotiations with current manufacturing and supply partners for the continuation of product manufacturing or supply in finished dosage form.

The license term will continue until the expiration of the last to expire licensed patents, unless terminated earlier. Also included in the filing is a Parent Guarantee by Scilex Holding Company, ensuring the performance of Scilex Pharma’s obligations under the licensing agreement.

This strategic move by OraMed aims to expand its product portfolio and market reach, leveraging Scilex’s developed lidocaine products. According to InvestingPro analysis, the company appears undervalued at its current trading price of $2.1, which is near its 52-week low. For investors seeking detailed insights, InvestingPro offers comprehensive analysis with additional ProTips and financial metrics to evaluate investment opportunities in undervalued pharmaceutical stocks.

In other recent news, Oramed Pharmaceuticals Inc . has announced the formation of a joint venture, OraTech Pharmaceuticals Inc., in collaboration with Hefei Tianhui Biotech Co., Ltd. Oramed will contribute its oral insulin and Protein Oral Delivery technology to OraTech, supported by a significant investment of $75 million, with $60 million from HTIT and $15 million from Oramed. Additionally, Oramed has extended the maturity date of a Senior Secured Promissory Note with Scilex Holding Company to December 31, 2025, as part of an amendment disclosed in an SEC filing. This amendment includes Oramed receiving 3,250,000 shares of Scilex common stock and introduces a covenant to prevent compensation increases for Scilex’s senior management while the note is outstanding. Oramed has also deferred a mandatory $6.25 million payment from Scilex to January 31, 2025, securing 5 million shares of Scilex common stock as collateral. Furthermore, Oramed confirmed the receipt of approximately $13.2 million from Scilex, applied towards a $15 million principal payment installment due in December 2024. These developments reflect Oramed’s strategic financial management and ongoing collaboration with Scilex.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.